ASSET AEvidence generation
CNS Complex Formulation Delivery
Designed to reduce total dose and systemic exposure while pursuing a more favorable therapeutic window.
Globally differentiated · Key evidence pendingPlatform: CNS delivery
PIPELINE
Five innovation assets
The website presents direction, intended function, stage and innovation positioning; product-specific information follows a controlled partnering process.
ASSET BPlatform development
Women’s Local Long-acting Delivery
Designed to stabilize local exposure, reduce handling burden and support long-term adherence.
Globally validated path · Delivery upgradePlatform: Women’s health
ASSET CPlatform development
Women’s Systemic Long-acting Delivery
Designed to reduce dosing frequency and support long-term, reversible and manageable care.
International frontier · Long-acting and manageablePlatform: Women’s health
ASSET DEvidence generation
Low-load Regenerative Material
Designed to provide structural support with less foreign material and align degradation with tissue replacement.
Global originality potential · Structure / conceptPlatform: Regenerative materials
ASSET EProof of concept
Solid-tumor Cell-delivery Enhancement
Designed to improve effector-cell tumor entry and support local microenvironment and killing activity.
Global originality potential · No identical public path foundPlatform: Cell delivery
Molecules, dosage forms, targets, formulations, raw data, IP and valuation information are disclosed only through a controlled partnering process.
BUILD THE NEXT VALUE INFLECTION
Turn the next asset into decision-grade evidence
Connect with BM Pharma on delivery platforms, co-development, translation and strategic partnerships.